Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Oncology

Pfizer pays $1 billion to develop Arvinas protein degrader

by Michael McCoy
July 23, 2021 | A version of this story appeared in Volume 99, Issue 27

 

Pfizer has struck a deal to develop ARV-471, a targeted protein degrader for metastatic breast cancer discovered by Arvinas. Pfizer will pay Arvinas $650 million up front and invest $350 million in the biotech firm. Protein degraders harness the body’s protein disposal system to degrade disease-causing proteins. ARV-471 targets the estrogen receptor, which can cause certain breast cancer cells to grow unchecked. Arvinas was founded in 2013 by Yale University chemical biologist Craig Crews. Pfizer first invested in the firm in 2018.

Article:

This article has been sent to the following recipient:

1 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.